Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(25)00376-6
Affiliations:
7
Authors:
26
Go to article
Institutions Authors Share
Zhongshan Hospital, Fudan University, China
22.333333
22.333333
22.333333
 0.86
Shenzhen University General Hospital, SZU, China
2.000000
 0.08
MOE Key Laboratory for Carcinogenesis and Invasion, China
1.416667
 0.05
Fudan University, China
0.250000
 0.01
Interested in Oncology and Carcinogenesis?